Peptide register

Small-molecule NNMT inhibitor studied preclinically; no registered human trials, no approval.

Synthetic analogue of the Semax peptide family; no registered human trials and no approval.

Proapoptotic peptidomimetic; early trial work stopped, no approval and no active development.

AMP-activated protein kinase activator trialled in the 1990s; not approved in any market.

Growth hormone fragment 176-191; drug development discontinued, no medicine approval.

Holds a food-ingredient status in the US, not a medicine approval

Synthetic pentadecapeptide studied mainly in animal models; no approval anywhere.

Australia: Schedule 4

Long-acting amylin analogue in phase 3 development; not approved anywhere.

Khavinson short-peptide bioregulator; no registered human trials and no approval as a medicine.

Growth-hormone-releasing hormone analogue without a drug affinity complex; not approved anywhere.

Long-acting growth-hormone-releasing hormone analogue; no approval in any market.

Nonapeptide first described in the 1970s; no marketing authorisation in any market.

Long-acting GLP-1 receptor agonist fusion protein; approved prescription medicine.

Synthetic tetrapeptide from the Khavinson bioregulator series; no approval in any market.

First licensed GLP-1 receptor agonist; approved prescription medicine since 2005.

Originator products discontinued in the US

D-retro-inverso peptide studied in rodent senescence models; no approval in any market.

Copper-binding tripeptide used as a cosmetic ingredient; not approved as an injectable medicine.

No approval as an injectable medicine

Growth-hormone-releasing peptide; single-dose studies in the 1990s, one registered trial abandoned in 2007, no approval anywhere.

Growth-hormone-releasing peptide; licensed in Japan as a diagnostic agent only.

Japan only, diagnostic use

Growth-hormone-releasing peptide; no approval as a medicine in any market.

Endogenous tripeptide antioxidant sold as an oral supplement; injectable forms are unapproved.

Injectable forms hold no marketing authorisation

Gonadotrophin-releasing hormone; approved prescription medicine in several European markets.

EU approvals only; US products discontinued

Growth-hormone-releasing peptide studied in the 1990s; no approval in any market.

Glycoprotein hormone; approved prescription medicine used in fertility and endocrine care.

Selective ghrelin receptor agonist; development discontinued, not approved in any market.

Decapeptide fragment of kisspeptin studied in reproductive medicine trials; not approved anywhere.

Tripeptide fragment of alpha-melanocyte-stimulating hormone; preclinical only, no approval.

Amino acid derivative sold as a supplement; a prescription form exists for carnitine deficiency.

A prescription levocarnitine medicine exists for carnitine deficiency

GLP-1 receptor agonist; approved prescription medicine since 2009.

Human cathelicidin antimicrobial peptide studied in phase 2 wound trials; not approved anywhere.

Dual glucagon and GLP-1 receptor agonist; approved as a prescription medicine in China in 2025.

China only

Melanocortin-1 receptor agonist; approved prescription medicine in the US and the EU.

Approved for a rare photodermatosis only

Non-selective melanocortin receptor agonist; never submitted for approval in any market.

Mitochondrial-derived 16-amino-acid peptide; one interventional human trial registered, no approval.

Coenzyme sold as an oral supplement; injectable forms hold no marketing authorisation.

Injectable forms hold no marketing authorisation

Posterior pituitary peptide hormone; long-established approved prescription medicine.

Spadin-derived TREK-1 channel blocker peptide; preclinical only, no approval anywhere.

Khavinson short-peptide bioregulator; no registered human trials and no approval as a medicine.

Triple GIP, GLP-1 and glucagon receptor agonist in phase 3; not approved anywhere.

Synthetic tuftsin analogue peptide; registered as a prescription medicine in Russia.

Russia only

GLP-1 receptor agonist; approved prescription medicine in the US and the EU.

Synthetic ACTH (4-10) fragment analogue; registered as a prescription medicine in Russia.

Russia only

GHRH fragment; former US prescription medicine (withdrawn 2009, not for safety), today compounded on prescription only.

Former US prescription medicine, withdrawn 2009 for non-safety reasons; today only compounded on prescription; named in the German prescription-only schedule

Small-molecule estrogen-related receptor agonist; preclinical only, no approval anywhere.

Cardiolipin-binding tetrapeptide; FDA-approved prescription medicine for Barth syndrome since 2025.

US only (Barth syndrome)

Synthetic peptide linked to the thymosin beta-4 sequence; no approval in any market.

Growth-hormone-releasing hormone analogue; approved prescription medicine for one indication.

Dual GIP and GLP-1 receptor agonist; approved prescription medicine.